健康元：健康元药业集团股份有限公司2024年年度报告

1 Important Notice I. The Board of Directors (the “Board”), the Board of Supervisors and directors, supervisorsand seniormanagement of the Company hereby warrant the truthfulness, accuracy andcompleteness of the contents of this annual report (the “Report”), and that there are no falserepresentations, misleading statements or material omissions contained in the Report, andseverally and jointly accept legal responsibility. II. All directors of the Company attended the Board meeting. III. Grant Thornton issued a standard unqualified audit report for the Company. IV. Mr. Zhu Baoguo (朱保国), theperson-in-charge of the Company, and Mr. Qiu Qingfeng(邱庆丰), the person-in-charge of accounting work,andMs. Guo Chenlu (郭琛璐),the person-in-charge of the accounting department (the head of the accounting department) declare thatthey hereby warrant the truthfulness, accuracy and completeness of the financial statementscontained in the Report. V. Profit distribution plan or plan for conversion of capital reserve to share capital approvedby the Board resolution during the Reporting Period Based on the audit conducted by Grant Thornton, as of 31 December 2024,the undistributed profitin the parent company statement of the Companyamounted to RMB2,635.7051 million.Pursuanttothe resolution of the Company's Board of Directors,the Company plans to distribute cashdividends for the fiscal year 2024, based on the total number of shares for dividend distribution,which is defined by the total shares of Company on the equity registration date designated by theannual profit distribution plan. The Company plans to distribute cash dividend of RMB2.00 (taxinclusive) for every 10 shares to all shareholders of the Company, and the remaining undistributedprofits will be carried forward to the following year. VI. Risk declaration for the forward-looking statements The Report contains forward-looking statements which involve the future plans, developmentstrategies, etc. of the Company, yet do not constitute substantive undertakings of the Company toinvestors. Investors should exercise caution prior to making investment decisions. VII. Whether there is non-operating use of funds by the controlling shareholder and theirrelated parties No VIII. Whether there is a violation of the prescribed decision-making procedures to provideexternal guaranteesNo IX. Whether more than half of directors cannot warrant the truthfulness, accuracy andcompleteness of the Report disclosed by the Company No X. Significant risk warnings There is no exceptionally significant risk that will have a material impact on the production andoperation of the Company during the Reporting Period. In this Report, the Company has elaboratedon the risks and countermeasures that the Company may face inthe course of production andoperation, including industry policy risk, market risk, risk of safety and environmental protection,risk in price and supply of raw materials and R&D risk. For more information, please refer to“Potential risks” part in Chapter 3 Management Discussion and Analysis. XI. Others □Applicable √N/A Table of Contents Important Notice.............................................................................................................................1Chairman's Statement....................................................................................................................4Financial Highlights........................................................................................................................7Chapter 1 Definitions......................................................................................................................9Chapter 2 Company Profile and Major Financial Indicators...................................................11Chapter 3 Management Discussion and Analysis......................................................................16Chapter 4 Corporate Governance...............................................................................................72Chapter 5 Environmental and Corporate Social Responsibility..............................................97Chapter 6Major Events.............................................................................................................125Chapter 7 Changes in Equity andShareholders......................................................................145Chapter 8 Information on Preferred Shares............................................................................152Chapter 9 Information on Bonds...............................................................................................153Chapter 10 Financial Statements...............................................................................................154 Chairman's Statement DearShareholders,Partners, and Colleagues, The year 2024 marked a period of profound transformation for China’s pharmaceutical industry. Asvolume-based procurement (VBP) policies continued to deepen, per